Challenges and opportunities in tuberculosis drug discovery: An industry perspective

Future Medicinal Chemistry

Volumn 5, Issue 5, 2013, Pages 499-501

  Shirude, Pravin S ^a   Ramachandran, Sreekanth ^a   Hosagrahara, Vinayak ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

alternative approach; cell based approach; target based approach; TB drug discovery

Indexed keywords

AMINOPYRAZINAMIDE DERIVATIVE; AZD 5847; BEDAQUILINE; PYRAZINAMIDE; PYRIMIDINE DERIVATIVE; QUINOLINYL PYRIMIDINE DERIVATIVE; SIRTURO; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL GENOME; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; ENZYME INHIBITION; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG DISCOVERY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84876100941     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.26     Document Type: Review

References (19)

1. World Health Organization. Global tuberculosis control report. WHO Press, Geneva, Switzerland (2011).
2. Dye C, Williams BG. The population dynamics and control of tuberculosis. Science 328, 856-861 (2010).
3. Zulma A, Hafner R, Leinhardt C, Hoelscher M, Nunn A. Advancing the development of tuberculosis therapy. Nat. Rev. Drug Discov. 11, 171-172 (2012).
4. Ginsberg A. The TB alliance: overcoming challenges to chart the future course of TB drug development. Future Med. Chem. 3, 1247-1252 (2011).
5. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223-227 (2005).
6. Gravestock MB, Acton DG, Betts MJ et al. New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chains. Bioorg. Med. Chem. Lett. 13, 4179-4186 (2003).
7. Silver LL. Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24, 71-109 (2011).
8. Simmons KJ, Chopra I, Fishwick CWG. Structure based discovery of antibacterial drugs. Nat. Rev. Microbiol. 8, 501-510 (2010).
9. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544 (1998).
10. Shirude PS, Paul B, Choudhury NR, Kedari C, Bandodkar B, Ugarkar B. Quinolinyl pyrimidines: potent inhibitors of NDH-2 as a novel class of anti-TB agents. ACS Med. Chem. Lett. 3, 736-740 (2012).
11. Shirude PS, Madhavapeddi P, Tucker JA et al. Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and non-replicating Mycobacterium tuberculosis. ACS Chem. Biol. 8(3), 519-523 (2013).
12. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40 (2007).
13. Sleigh SH, Barton CL. Repurposing strategies for therapeutics. Pharm. Med. 24, 151-159 (2010).
14. Reaume AG. Drug repurposing through nonhypothesis driven phenotypic screening. Drug Discov. Today Ther. Strateg. 8, 85-88 (2011).
15. Palomino JC, Martin A. Is repositioning of drugs a viable alternative in the treatment of tuberculosis. J. Antimicrob. Chemother. 68(2), 275-283 (2013).
16. Working group on new TB drugs. www.newtbdrugs.org/pipeline.php
17. Global alliance for TB. www.tballiance.org/pipeline/pipeline.php
18. Johnson and Johnson. Situro FDA advanced grant accelerated approval. www.investor.jnj.com/releaseDetail. cfm?ReleaseID=730893&year=2013
19. Phase 2a EBA Trial of AZD5847. www.clinicaltrials.gov/ct2/show/ NCT01516203